Sign In
Buy ADVM
$4.36
+0 (+0%)
At Close: Mar 06, 2026
Why Adverum Biotechnologies Stock Is Plummeting Today
03:54pm, Thursday, 29'th Apr 2021
Adverum Biotechnologies (NASDAQ: ADVM) shares are trading lower after the company announced a Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical trial evaluating ADVM-0
The Sonic Fund II, L.P. Comments on Adverum Biotechnologies Update Regarding INFINITY Phase 2 Trial of ADVM-022
02:58pm, Thursday, 29'th Apr 2021
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Com
Why Adverum Biotechnologies Stock Is Imploding Today
11:48am, Thursday, 29'th Apr 2021
Investors are running for the hills following the company's latest clinical update.
ADVM Stock: From $10.16 To $4.70 Pre-Market Explanation
08:25am, Thursday, 29'th Apr 2021
The stock price of Adverum Biotechnologies Inc (NASDAQ: ADVM) fell from $10.16 to $4.70 pre-market. This is why it happened.
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
04:01pm, Wednesday, 28'th Apr 2021
REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant
The Sonic Fund II, L.P. Issues Presentation Detailing Compelling Case for Immediate Board Upgrade at Adverum Biotechnologies, Inc.
05:00pm, Thursday, 22'nd Apr 2021
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Com
Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum's Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D.
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
08:00am, Wednesday, 21'st Apr 2021
Sonic's Nominees Lack Experience and Qualifications to Advance Adverum's Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
08:05am, Friday, 16'th Apr 2021
-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT -- REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM),
HONOLULU, April 8, 2021 /PRNewswire/ -- The Sonic Fund II, L.P. ("Sonic"), which beneficially owns approximately 6.7% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (t
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
05:10pm, Wednesday, 17'th Mar 2021
Responds to Intent to Nominate Directors from Sonic Fund
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
09:09am, Friday, 05'th Mar 2021
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
Adverum Biotechnologies, Inc's (ADVM) CEO Laurent Fischer on Q4 2020 Results - Earnings Call Transcript
11:24pm, Monday, 01'st Mar 2021
Adverum Biotechnologies, Inc's (ADVM) CEO Laurent Fischer on Q4 2020 Results - Earnings Call Transcript
Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates
06:12pm, Monday, 01'st Mar 2021
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -21.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the
Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call Key Opinion Leader Arsha
